Short answer: the EU's revised wastewater directive makes producers of cosmetics and medicines finance the removal of micropollutants from urban wastewater — at least 80% of the specified treatment and monitoring costs, collected through national schemes. It is not a levy on your formula and not a fixed rate: your share is derived from how much of which substances you place on the market. Budget for it as a per-market cost line from 2029, and treat the pending legal challenge as a reason to track, not to delete the line.
This is the rare compliance cost that arrives without touching your formulation. Nothing about it requires a reformulation, a new test or a changed certificate — which is exactly why it is easy to miss. It lands on the commercial side of the business, as a recurring fee tied to sales volume in a market, and the reporting behind it reaches further into your formulation records than most brand teams expect.
What the obligation actually is
The revised Urban Wastewater Treatment Directive — Directive (EU) 2024/3019 — added a fourth treatment stage to wastewater plants, aimed at micropollutants that pass through conventional treatment. It then applied the polluter-pays principle to the upgrade: producers of products that contribute those micropollutants are required to finance the bulk of it.
Three features define the exposure:
- A minimum share, not a cap. Affected producers must cover at least 80% of the specified quaternary-treatment and micropollutant-monitoring costs, with product-data gathering, verification and the administrative cost of running the scheme on top.
- National implementation. Member states transpose the directive into national law and set up the producer responsibility arrangements. You will deal with as many schemes as markets you sell in.
- A product-data obligation. Contributions are determined from the quantities and the hazardousness in wastewater of the substances in the products placed on the market, supported by annual information on quantities, hazardousness, biodegradability and any exemption claimed.
The cost lines, itemised
| Cost component | What it covers | Who carries it |
|---|---|---|
| Quaternary treatment financing | At least 80% of the investment and operating cost of the advanced treatment stage | Affected producers, collected through the national scheme |
| Micropollutant monitoring | Measurement programmes at treatment plants | Affected producers, in the same share |
| Product-data gathering and verification | Establishing and validating what substances your products put into the system | Affected producers |
| Scheme administration | Running the producer responsibility body itself | Affected producers |
| Reporting and records | Annual information on quantities, hazardousness, biodegradability and claimed exemptions | The producer, as an internal cost |
The last two lines are the ones that surprise finance teams. The fee is visible once a rate exists; the record-keeping behind it is a permanent internal workload, and it is proportional to portfolio width rather than to revenue.
What drives your number
Five variables decide the size of the bill, and only one of them is about volume.
- Tonnage of substances placed on the market in the market concerned — not units, not revenue. A heavy, water-based product with a large preservative and surfactant load is not assessed the same way as a lightweight anhydrous formula.
- Hazardousness of those substances in wastewater, which is where the attribution methodology matters. The figures being challenged in court are precisely the toxicity-weighting and attribution values used to work out which substances count towards which sector.
- Biodegradability. A substance that degrades readily in wastewater is treated differently from a persistent one, which is the practical reason a reformulation decision can turn into an EPR decision.
- Exemptions. Producers can be exempted where the substances they place on the market total less than one tonne a year, or where those substances are rapidly biodegradable in wastewater or generate no micropollutants at end of life. Volume matters here in a way it does not for MOQ purposes.
- The number of national schemes you are in. Each market has its own body, its own reporting format and its own filing dates.
Our own per-unit cost walkthrough covers the cost drivers a buyer controls at development stage. This one sits outside that list, which is the point: it is a market-presence cost rather than a product cost.
The legal challenge, and why it does not pause your planning
The attribution of these costs to the cosmetics and medicines sectors has been contested from the start, and in 2026 the challenge reached the EU courts.
In early September 2026 an Advocate General of the Court of Justice delivered an opinion on a member state's action, recommending annulment of the provisions that require producers of medicines and cosmetics to finance the quaternary treatment stage. The reasoning was not that the polluter-pays principle is wrong — the opinion upheld applying it to fund advanced treatment — but that there was reasonable doubt about the accuracy of key toxicity-weighting values and about attributing certain substances to the cosmetics sector, which undermined the proportionality analysis.
Separately, a European trade association's own action was dismissed as inadmissible, on the basis that the association lacked standing; a member state cannot be blocked that way, which is why the state action is the one that runs.
Two weeks after the opinion, a group of member states wrote to the Commission asking for an independent reassessment of the cost base and a transparent method for attributing micropollutants to sectors, and floating temporary adjustments or suspension of the related deadlines if that reassessment identifies serious shortcomings. The letter is a request, not a change in the law, and the directive itself is unamended. The Commission's response is the next thing worth watching.
The planning conclusion is deliberately unromantic: keep the cost line, track the litigation, and build the data capability now, because if the provisions survive, the reporting obligation starts on a fixed date regardless of when the final ruling lands.
Where the estimate breaks
Cost models for this fee break in four predictable places.
- Ignoring the data cost. The fee looks like a rate on a tonnage figure; the tonnage figure has to be constructed from formulation records, batch records and change control, and it has to be defensible annually. Brands that keep ingredient quantities only in a formulator's file will pay for that twice.
- Assuming a single flat rate. Contributions are built from quantities and hazardousness of substances placed on the market, so two SKUs of the same size can generate different charges.
- Missing the exempt-in-one-market trap. The exemption thresholds are tested against what you place on that market. Same product, different destination, different answer.
- Forgetting the reformulation lever. Substituting a persistent substance for one that degrades readily in wastewater is a formulation decision that happens to reduce a recurring cost. It is the only lever in this scheme that a manufacturer-side project can move, and it is also the lever already pulled for other reasons — which is why the same change can serve several compliance tracks at once, as we set out in what a forced reformulation costs.
Building the file now
The work that pays off later is unglamorous data work:
- A per-SKU substance inventory with quantities, expressed in the form a national scheme will ask for
- A biodegradability position for each substance, sourced from supplier data rather than assumed
- A hazard classification per substance, mapped once and reused across markets
- A change-control link, so a reformulation or a supplier switch updates the EPR file rather than silently invalidating it
- An ownership decision inside the company: this data has to come from formulation records, but it is collected, filed and defended by whoever owns market compliance
For brands selling into Europe, this sits alongside the packaging and environmental-claim obligations that took effect during 2026 rather than replacing them — the packaging and green-claims rules and the ingredient restriction programme both reach further into formulation. Our Europe and UK market notes collect the destination-specific requirements we work to for orders entering that market.
FAQ
Q: Is the wastewater EPR fee a fixed amount per product? A: No. Contributions are determined from the quantities and hazardousness in wastewater of the substances in the products you place on the market, so the charge varies by formulation, not only by volume. A rate exists only once a national scheme exists to charge it.
Q: When do the obligations start? A: Member states transpose the directive into national law by 31 July 2027 and have to ensure that affected producers have producer responsibility arrangements in place by 31 December 2028, which is why 2029 is the realistic first billing year. The product-data work runs earlier, because the data has to exist before it can be reported.
Q: Can my brand be exempted? A: Two exemption routes exist: substances placed on the market totalling less than one tonne a year, or substances that are rapidly biodegradable in wastewater or generate no micropollutants at end of life. Both are tested against what you place on the specific market, so the same product range can be in scope in one country and exempt in another.
Q: Does the pending court challenge mean I can ignore it for now? A: No. The Advocate General's opinion recommended annulment of the producer-financing provisions, but an opinion is not a judgment and the directive remains in force. The request from member states for a reassessment is a request, not an amendment. The prudent position is to keep the cost line and build the data capability while the case proceeds.
Q: Does this change what I should ask my manufacturer for? A: Yes, in one respect: per-substance quantities with supplier-backed biodegradability data, delivered in a structured form you can reuse per market. That is the same ingredient-level information the documentation package already touches, and it becomes more valuable once a recurring fee depends on it.